Investor relations

Investor relations

CEO Comments November 11, 2022

The AGENT study showed neither any clinical or commercial value

Given the AGENT study results’ low clinical and business value for Isofol, we began work during the quarter to terminate the study. This must be carried out in accordance with applicable ethical aspects and regulatory requirements. This work is extensive and will therefore require both time and resources throughout autumn 2022 and the beginning of 2023. We also took active measures to reduce costs and secure the company’s financial position, which has been our utmost priority along with finding any positive outcomes in the study data and terminating the study”, says CEO Ulf Jungnelius.

Ulf Jungnelius

Ulf Jungnelius - CEO


About the AGENT study

Want to know more about the AGENT study and the drug candidate arfolitxorin?

Read more

Last updated 11-11-2022